查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1797670

女性的健康相关POC检验的全球市场:产品类型·年龄·样品类型·检验类型·技术·用途·通路·终端用户·各地区 (～2032年)

Global Point-of-Care Testing for Women Health Market Research by Product, by Age, by Sample Type, by Test Type, by Technology, by Application, by Distribution Channel, by End User, and by Region Forecast till 2032
出版日期: | 出版商: Market Research Future | 英文 350 Pages | 订单完成后即时交付

价格

预计到 2032 年，全球女性健康即时检测市场规模将成长至 287.7 亿美元，2024 年至 2032 年的复合年增长率为 6.26%。 女性健康即时检测是一种用途广泛、易于取得的诊断工具，可为生殖健康、传染病和妊娠相关併发症等重症疾病提供即时、便携的检测结果。该检测最初是为残障人士开发的，现在已可在医院、诊所和家中使用。它们快速、经济、可靠，是预防保健和在严重併发症发生前进行早期介入的重要组成部分。

性传染病 (STI)、泌尿道感染 (UTI) 和人类乳突病毒 (HPV) 等常见女性疾病的增多，凸显了快速检测工具的紧迫性。即时检测 (POC) 能够提供快速可靠的结果，支持早期诊断和干预，从而应对这项课题。女性健康在很大程度上依赖及时治疗和便捷的检测方案，而日益加重的传染病负担也推动了快速检测的普及。

区域分析

受消费者对快速可靠检测需求的推动，北美市场正在不断扩张。较高的认知度和完善的医疗保健系统使其在医院和家庭护理机构中广泛应用。到2023年，美国将以57.3544亿美元的市场规模引领北美市场，其次是加拿大（8.8972亿美元）和墨西哥（4.2632亿美元）。

欧洲市场正经历强劲的创新，并日益重视个人化医疗。尖端诊断平台的应用正在不断扩大，主要用于从生殖健康到慢性病等各种疾病的早期检测。 2023年，德国、英国和法国分别以12.2006亿美元、9.6019亿美元和7.7511亿美元的市场规模位列欧洲前三名。

受中国、印度和东南亚医疗服务可近性的不断扩大推动，亚太地区展现出巨大的成长潜力。预计到2023年，中国（7.5165亿美元）、印度（6.3481亿美元）和日本（6.0731亿美元）将成为主要市场。妊娠相关併发症和慢性疾病的增多，推动了对POCT解决方案的依赖性。

本报告探讨了全球女性健康POCT市场，提供了市场定义和概述、影响市场成长的各种因素分析、市场规模趋势和预测、按细分市场、地区和主要国家/地区细分、竞争格局以及主要公司概况。

目录

第1章 摘要整理

第2章 市场概要

第3章 调查手法

第4章 市场动态

  • 促进因素
    • 女性传染病病率高
    • 女性不孕症率上升
    • 扩大与女性健康即时检测相关的策略性举措
  • 阻碍因素
    • 即时诊断侦测的准确性
  • 机遇
    • 提高认知度与健康倡议
    • 诊断影像系统成本高以及程序

第5章 市场要素分析

  • 波特的五力分析
  • COVID-19对全球女性的健康相关POC检验市场带来的影响
  • 消费者偏好分析
  • 胶体金产品的监管环境与环境考量
  • 从 IVDD 到 IVDR 过渡的市场影响

第6章 全球女性的健康相关POC检验市场:各产品

  • 概要
  • 设备/设备
  • 试剂和套件
  • 消耗品

第7章 全球女性的健康相关POC检验市场:各年龄

  • 概要
  • 青春期
  • 成人
  • 老年人

第8章 全球女性的健康相关POC检验市场:样品类别

  • 概要
  • 血清
  • 等离子
  • 全血
  • 尿
  • 其他

第9章 全球女性的健康相关POC检验市场:检验类别

  • 概要
  • 睪固酮检验
  • 雌二醇检验
  • 抗穆氏管荷尔蒙检验
  • 催乳激素检验
  • 孕酮检验
  • 滤泡促素检验
  • 黄体激素检验
  • B-HCG检验
  • 其他

第10章 全球女性的健康相关POC检验市场:各技术

  • 概要
  • 胶体金侧流化验
  • 萤光免疫化验
  • 实验室晶片
  • 其他

第11章 全球女性的健康相关POC检验市场:各用途

  • 概要
  • 妊娠糖尿病
  • 阴道感染疾病
  • 泌尿道感染
  • 子宫颈癌症或前癌症状态
  • 血红素缺乏症
  • 乳癌
  • 甲状腺疾病
  • 性感染疾病
    • 披衣菌感染
    • 淋病
    • HIV
    • 梅毒
    • 其他
  • 妊娠可能条件
    • 多囊性卵巢症候群
    • 排卵障碍
    • 其他
  • 妊娠检验
  • 其他

第12章 全球女性的健康相关POC检验市场:各流通管道

  • 概要
  • 离线
    • 医院药局
    • 零售药局
    • 大卖场/超级市场
  • 线上
    • 电子商务平台
    • 线上药局

第13章 全球女性的健康相关POC检验市场:各终端用户

  • 概要
  • 医院
  • 诊断实验室
  • 居家照护
  • 其他

第14章 全球女性的健康相关POC检验市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • 东南亚
    • 其他
  • 全球其他地区
    • 中东·非洲
    • 南美

第15章 竞争情形

  • 市场占有率分析
  • 竞争仪表板
  • 上市公司的股票:摘要
  • 比较分析:主要企业的财务
  • 主要的展开·成长策略

第16章 企业简介

  • SWISS PRECISION DIAGNOSTICS GMBH-CLEARBLUE
  • WONDFO
  • CHURCH & DWIGHT CO., INC.-FIRST RESPONSE
  • HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.
  • W.H.P.M., INC.
  • SEKISUI DIAGNOSTICS
  • INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD
  • YANGZHOU VIOMED
  • COFOE MEDICAL TECHNOLOGY CO., LTD.
  • CHUNGDO PHARM CO., LTD.
  • ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.
  • EASY HEALTHCARE CORPORATION

第17章 资料的引用

Product Code: MRFR/HC/58150-CR

Global Point-of-Care Testing for Women Health Market Research by Product (Instruments/ Devices, Reagents & Kits, Consumables), by Age (Adolescent, Adult, Geriatric), by Sample Type (Serum, Plasma, White Blood, Urine, Others), by Test Type (Testosterone Test, Estradiol Test, Anti- Mullerian Hormone Test, Prolactin Test, Progesterone Test, Follicle-Stimulating Hormone Test, Luteinizing Hormone Test, B-hCG Test, Others), by Technology (Colloidal Gold Lateral Flow Assays, Fluorescence Immunoassays, Lab-on-a-Chip, Others), by Application (Gestational Diabetes, Vaginal Infection, Urinary Tract Infection, Cervical Cancer or Pre-Cancerous Conditions, Hemoglobin Deficiency, Breast Cancer, Thyroid Disease, Sexually Transmitted Infections, Fertility Conditions, Pregnancy Testing, Others), by Distribution Channel (Offline, Online), by End User (Hospitals, Diagnostic Laboratories, Home Settings, Others), and by Region (North America, Europe, Asia Pacific, Rest of the World) Forecast till 2032

Industry Overview

The Global Point-of-Care Testing for Women's Health Market is forecasted to expand to USD 28.77 billion by 2032, reflecting a steady 6.26% CAGR during 2024-2032. POCT for women's health is a multipurpose, easy-to-access diagnostic tool giving immediate and on-the-go results of critical conditions, such as reproductive health, infectious diseases, and pregnancy-related complications. Originally intended for the disabled, these tests are also accessible at hospitals, clinics, or simply at home. Their rapidity, and at the same time, good affordability and reliability allow them to become keys in the whole preventive care and early medical intervention process serious cases.

Growing cases of sexually transmitted infections, urinary tract infections, and HPV among women highlight the urgent need for rapid detection tools. POC testing addresses this gap with quick and reliable results, supporting early diagnosis and intervention. The rising infection burden is propelling adoption, as women's health outcomes depend on timely treatment and accessible testing solutions.

Key Company Development

Swiss Precision Diagnostics GmbH has demonstrated consistent innovation in advancing diagnostic solutions for women's health. In August 2023, the company launched the Clearblue Menopause Stage Indicator, a first-of-its-kind home-use product that evaluates menopause stages by integrating urinary FSH measurements with age and cycle data. This innovation empowers women with greater understanding of reproductive transitions, fostering informed health decisions. Complementing this milestone, SPD in August 2020 implemented the Matrix Gemini LIMS to optimize data management in pregnancy studies. This technology enhanced accessibility, streamlined laboratory workflows, and improved biobank operations, reflecting the company's strong emphasis on digital transformation. These strategic moves reinforce SPD's leadership in combining product innovation and advanced technologies to deliver precision-driven women's health diagnostics.

Key Players

Major players in the global point-of-care testing for women health market are Swiss Precision Diagnostics GmbH (SPD), Wondfo, Church & Dwight Co., Inc., Hangzhou Singclean, Medical Products Co., Ltd., W.H.P.M., Inc., SEKISUI Diagnostics, Innovita Biological Technology Co., Ltd., Yangzhou VIOMED, Cofoe Medical Technology Co., Ltd., and Chungdo Pharm Co., Ltd.

Report Attribute Details

Market Size 2023 USD 16,627.22 Million

Market Size 2032 USD 28,768.16 Million

CAGR (2024-2032) 6.26%

Base Year 2023

Market Forecast Period 2024-2032

Historical Data 2019-2024

Industry Segmentations CAGR (2024-2032)

By Product: Instruments/ Devices - 7.72%, Reagents & Kits - 5.97%.

By Age: Adolescent - 8.18%, Adult - 6.20%.

By Sample Type: Serum - 5.27%, Plasma - 4.30%.

By Test Type: Testosterone Test - 4.12%, Estradiol Test - 3.53%.

By Technology: Colloidal Gold Lateral Flow Assays - 7.19%, Fluorescence Immunoassays - 5.46%.

By Application: Gestational Diabetes - 5.34%, Vaginal Infection - 4.08%.

By Distribution Channel: Offline - 5.49%, Online - 7.35%.

By End User: Hospitals - 5.42 %, Diagnostic Laboratories - 6.96%.

Regional Analysis

The women's health POCT market in North America rides on the back of consumer demand for quick and reliable testing. High awareness in conjunction with well-organized healthcare systems acts as a springboard for wide use in hospital as well as home-care environments. In 2023, North America's market was led by the US, followed by Canada and Mexico, with respective market values of USD 5,735.44 million, USD 889.72 million, and USD 426.32 million.

Innovation is thriving in the European market, and there is an increasing emphasis on personalized medicine. The use of cutting-edge diagnostic platforms is growing, with the primary objective being early detection of diseases that range from reproductive health to chronic conditions. In 2023, Germany, the UK, and France were the top three European markets, contributing USD 1,220.06 million, USD 906.19 million, and USD 775.11 million.

Asia-Pacific demonstrates remarkable growth potential, propelled by expanding healthcare access in China, India, and Southeast Asia. In 2023, the APAC region China, India, and Japan, is the leading market, with market sizes of USD 751.65 million, USD 634.81 million, and USD 607.31 million. A rising incidence of pregnancy-related complications and chronic illnesses is driving reliance on POCT solutions.

Markets in the Middle East, Africa, and South America are witnessing steady adoption of POCT, largely due to limited access to traditional laboratory infrastructure. Portable diagnostic technologies are emerging as vital tools in addressing reproductive health challenges.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
  • 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
  • 3.7 DATA FORECASTING
    • 3.7.1 DATA FORECASTING TYPE
  • 3.8 DATA MODELING
    • 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.8.2 DATA MODELING:
  • 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES IN WOMEN
    • 4.2.2 INCREASING CASES OF INFERTILITY AMONG WOMEN
    • 4.2.3 GROWING STRATEGIC INITIATIVES ASSOCIATED WITH THE POINT-OF-CARE TESTING FOR WOMEN HEALTH
  • 4.3 RESTRAINTS
    • 4.3.1 INACCURACY OF POINT OF CARE DIAGNOSTIC TESTS
  • 4.4 OPPORTUNITY
    • 4.4.1 RISING AWARENESS AND HEALTH INITIATIVES
    • 4.4.2 HIGH COST OF DIAGNOSTIC IMAGING SYSTEMS AND PROCEDURES

5 MARKET FACTOR ANALYSIS

  • 5.1 PORTER'S FIVE FORCES MODEL
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 THREAT OF SUBSTITUTES
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF RIVALRY
  • 5.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET
  • 5.3 CONSUMER PREFERENCE ANALYSIS
  • 5.4 REGULATORY LANDSCAPE AND ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS
    • 5.4.1 REGULATORY LANDSCAPE
    • 5.4.2 ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS
  • 5.5 EFFECTS OF TRANSITION OF IVDD TO IVDR ON GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET

6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT

  • 6.1 OVERVIEW
  • 6.2 INSTRUMENTS/DEVICES
  • 6.3 REAGENTS & KITS
  • 6.4 CONSUMABLES

7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE

  • 7.1 OVERVIEW
  • 7.2 ADOLESCENT
  • 7.3 ADULT
  • 7.4 GERIATRIC

8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE

  • 8.1 OVERVIEW
  • 8.2 SERUM
  • 8.3 PLASMA
  • 8.4 WHOLE BLOOD
  • 8.5 URINE
  • 8.6 OTHERS

9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE

  • 9.1 OVERVIEW
  • 9.2 TESTOSTERONE TEST
  • 9.3 ESTRADIOL TEST
  • 9.4 ANTI-MULLERIAN HORMONE TEST
  • 9.5 PROLACTIN TEST
  • 9.6 PROGESTERONE TEST
  • 9.7 FOLLICLE-STIMULATING HORMONE TEST
  • 9.8 LUTEINIZING HORMONE TEST
  • 9.9 B-HCG TEST
  • 9.10 OTHERS

10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY

  • 10.1 OVERVIEW
  • 10.2 COLLOIDAL GOLD LATERAL FLOW ASSAYS
  • 10.3 FLUORESCENCE IMMUNOASSAYS
  • 10.4 LAB-ON-A-CHIP
  • 10.5 OTHERS

11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION

  • 11.1 OVERVIEW
  • 11.2 GESTATIONAL DIABETES
  • 11.3 VAGINAL INFECTION
  • 11.4 URINARY TRACT INFECTION
  • 11.5 CERVICAL CANCER OR PRE-CANCEROUS CONDITIONS
  • 11.6 HEMOGLOBIN DEFICIENCY
  • 11.7 BREAST CANCER
  • 11.8 THYROID DISEASE
  • 11.9 SEXUALLY TRANSMITTED INFECTIONS
    • 11.9.1 CHLAMYDIA
    • 11.9.2 GONORRHEA
    • 11.9.3 HIV
    • 11.9.4 SYPHILIS
    • 11.9.5 OTHERS
  • 11.10 FERTILITY CONDITIONS
    • 11.10.1 POLYCYSTIC OVARY SYNDROME
    • 11.10.2 OVULATION DISORDERS
    • 11.10.3 OTHERS
  • 11.11 PREGNANCY TESTING
  • 11.12 OTHERS

12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL

  • 12.1 OVERVIEW
  • 12.2 OFFLINE
    • 12.2.1 HOSPITAL PHARMACIES
    • 12.2.2 RETAIL PHARMACIES
    • 12.2.3 HYPERMARKET/SUPERMARKET
  • 12.3 ONLINE
    • 12.3.1 E-COMMERCE PLATFORMS
    • 12.3.2 ONLINE PHARMACIES

13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 HOSPITALS
  • 13.3 DIAGNOSTIC LABORATORIES
  • 13.4 HOME SETTINGS
  • 13.5 OTHERS

14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION

  • 14.1 OVERVIEW
  • 14.2 NORTH AMERICA
    • 14.2.1 US
    • 14.2.2 CANADA
    • 14.2.3 MEXICO
  • 14.3 EUROPE
    • 14.3.1 GERMANY
    • 14.3.2 FRANCE
    • 14.3.3 UK
    • 14.3.4 ITALY
    • 14.3.5 SPAIN
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA-PACIFIC
    • 14.4.1 CHINA
    • 14.4.2 INDIA
    • 14.4.3 JAPAN
    • 14.4.4 AUSTRALIA
    • 14.4.5 SOUTH KOREA
    • 14.4.6 SOUTH EAST ASIA
      • 14.4.6.1 MALAYSIA
      • 14.4.6.2 SINGAPORE
      • 14.4.6.3 THAILAND
      • 14.4.6.4 VIETNAM
      • 14.4.6.5 PHILIPPINES
      • 14.4.6.6 INDONESIA
      • 14.4.6.7 REST OF SOUTH EAST ASIA
    • 14.4.7 REST OF ASIA-PACIFIC
  • 14.5 REST OF THE WORLD
    • 14.5.1 MIDDLE EAST & AFRICA
    • 14.5.2 SOUTH AMERICA
      • 14.5.2.1 BRAZIL
      • 14.5.2.2 ARGENTINA
      • 14.5.2.3 CHILE
      • 14.5.2.4 REST OF SOUTH AMERICA

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 MARKET SHARE ANALYSIS, 2023
  • 15.3 COMPETITOR DASHBOARD
  • 15.4 PUBLIC PLAYERS STOCK SUMMARY
  • 15.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
  • 15.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 15.6.1 PRODUCT LAUNCH
    • 15.6.2 TECHNOLOGY LAUNCH
    • 15.6.3 AQUISITION
    • 15.6.4 PRODUCT RECOGNITION

16 COMPANY PROFILES

  • 16.1 SWISS PRECISION DIAGNOSTICS GMBH - CLEARBLUE
    • 16.1.1 COMPANY OVERVIEW
    • 16.1.2 PRODUCTION OVERVIEW
    • 16.1.3 FINANCIAL OVERVIEW
    • 16.1.4 PRODUCTS OFFERED
    • 16.1.5 DISTRIBUTION CHANNEL
    • 16.1.6 PRICE ANALYSIS
    • 16.1.7 PROMOTION STRATEGY
    • 16.1.8 TECHNOLOGY ANALYSIS
    • 16.1.9 KEY DEVELOPMENTS
    • 16.1.10 SWOT ANALYSIS
    • 16.1.11 KEY STRATEGIES
  • 16.2 WONDFO
    • 16.2.1 COMPANY OVERVIEW
    • 16.2.2 PRODUCTION OVERVIEW
    • 16.2.3 FINANCIAL OVERVIEW
    • 16.2.4 PRODUCTS OFFERED
    • 16.2.5 TECHNOLOGY
    • 16.2.6 KEY DEVELOPMENTS
    • 16.2.7 SWOT ANALYSIS
    • 16.2.8 KEY STRATEGIES
  • 16.3 CHURCH & DWIGHT CO., INC. - FIRST RESPONSE
    • 16.3.1 COMPANY OVERVIEW
    • 16.3.2 PRODUCTION OVERVIEW
    • 16.3.3 FINANCIAL OVERVIEW
    • 16.3.4 PRODUCTS OFFERED
    • 16.3.5 DISTRIBUTION CHANNEL
    • 16.3.6 PRICE ANALYSIS
    • 16.3.7 PROMOTION
    • 16.3.8 TECHNOLOGY ANALYSIS
    • 16.3.9 KEY DEVELOPMENTS
    • 16.3.10 SWOT ANALYSIS
    • 16.3.11 KEY STRATEGIES
  • 16.4 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.
    • 16.4.1 COMPANY OVERVIEW
    • 16.4.2 PRODUCTION OVERVIEW
    • 16.4.3 FINANCIAL OVERVIEW
    • 16.4.4 PRODUCT OFFERED
    • 16.4.5 TECHNOLOGY ANALYSIS
    • 16.4.6 KEY DEVELOPMENTS
    • 16.4.7 KEY STRATEGIES
  • 16.5 W.H.P.M., INC.
    • 16.5.1 COMPANY OVERVIEW
    • 16.5.2 PRODCUTION OVERVIEW
    • 16.5.3 FINANCIAL OVERVIEW
    • 16.5.4 PRODUCTS OFFERED
    • 16.5.5 TECHNOLOGY ANALYSIS
    • 16.5.6 KEY DEVELOPMENTS
    • 16.5.7 KEY STRATEGIES
  • 16.6 SEKISUI DIAGNOSTICS
    • 16.6.1 COMPANY OVERVIEW
    • 16.6.2 PRODUCTION OVERVIEW
    • 16.6.3 FINANCIAL OVERVIEW
    • 16.6.4 PRODUCTS OFFERED
    • 16.6.5 TECHNOLOGY ANALYSIS
    • 16.6.6 KEY DEVELOPMENTS
    • 16.6.7 SWOT ANALYSIS
    • 16.6.8 KEY STRATEGIES
  • 16.7 INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD
    • 16.7.1 COMPANY OVERVIEW
    • 16.7.2 FINANCIAL OVERVIEW
    • 16.7.3 PRODUCTS OFFERED
    • 16.7.4 TECHNOLOGY ANALYSIS
    • 16.7.5 KEY DEVELOPMENTS
    • 16.7.6 KEY STRATEGIES
  • 16.8 YANGZHOU VIOMED
    • 16.8.1 COMPANY OVERVIEW
    • 16.8.2 PRODUCTION OVERVIEW
    • 16.8.3 FINANCIAL OVERVIEW
    • 16.8.4 PRODUCTS OFFERED
    • 16.8.5 TECHNOLOGY ANALYSIS
    • 16.8.6 KEY DEVELOPMENTS
    • 16.8.7 KEY STRATEGIES
  • 16.9 COFOE MEDICAL TECHNOLOGY CO., LTD.
    • 16.9.1 COMPANY OVERVIEW
    • 16.9.2 PRODUCTION OVERVIEW
    • 16.9.3 FINANCIAL OVERVIEW
    • 16.9.4 PRODUCTS OFFERED
    • 16.9.5 KEY DEVELOPMENTS
    • 16.9.6 TECHNOLOGY ANALYSIS
    • 16.9.7 SWOT ANALYSIS
    • 16.9.8 KEY STRATEGIES
  • 16.10 CHUNGDO PHARM CO., LTD.
    • 16.10.1 COMPANY OVERVIEW
    • 16.10.2 PRODUCTION OVERVIEW
    • 16.10.3 FINANCIAL OVERVIEW
    • 16.10.4 PROUDCTS OFFERED
    • 16.10.5 TECHNOLOGY ANALYSIS
    • 16.10.6 KEY DEVELOPMENTS
    • 16.10.7 KEY STRATEGIES
  • 16.11 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.
    • 16.11.1 COMPANY OVERVIEW
    • 16.11.2 PRODUCTION OVERVIEW
    • 16.11.3 FINANCIAL OVERVIEW
    • 16.11.4 PRODUCTS OFFERED
    • 16.11.5 TECHNOLOGY ANALYSIS
    • 16.11.6 KEY DEVELOPMENTS
    • 16.11.7 SWOT ANALYSIS
    • 16.11.8 KEY STRATEGIES
  • 16.12 EASY HEALTHCARE CORPORATION
    • 16.12.1 COMPANY OVERVIEW
    • 16.12.2 PRODUCTION OVERVIEW
    • 16.12.3 FINANCIAL OVERVIEW
    • 16.12.4 PRODUCTS OFFERED
    • 16.12.5 TECHNOLOGY
    • 16.12.6 KEY DEVELOPMENTS
    • 16.12.7 KEY STRATEGIES

17 DATA CITATIONS

LIST OF TABLES

  • TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
  • TABLE 2 DIFFERENCE BETWEEN IVDD & IVDR
  • TABLE 3 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 4 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR INSTRUMENTS/DEVICES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 5 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR REAGENTS & KITS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR CONSUMABLES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ADOLESCENT, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ADULT, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GERIATRIC, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SERUM, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PLASMA, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR WHOLE BLOOD, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 15 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR URINE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 16 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 17 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 18 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR TESTOSTERONE TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 19 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ESTRADIOL TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 20 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ANTI-MULLERIAN HORMONE TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 21 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PROLACTIN TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 22 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PROGESTERONE TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 23 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FOLLICLE-STIMULATING HORMONE TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 24 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR LUTEINIZING HORMONE TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 25 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR B-HCG TEST, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 26 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 27 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 28 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR COLLOIDAL GOLD LATERAL FLOW ASSAYS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 29 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FLUORESCENCE IMMUNOASSAYS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 30 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR LAB-ON-A-CHIP, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 31 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 32 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 33 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GESTATIONAL DIABETES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 34 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR VAGINAL INFECTION, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 35 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR URINARY TRACT INFECTION, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 36 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR CERVICAL CANCER OR PRE-CANCEROUS CONDITIONS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 37 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HEMOGLOBIN DEFICIENCY, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 38 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR BREAST CANCER, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 39 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR THYROID DISEASE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 40 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 41 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 42 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR CHLAMYDIA, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 43 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GONORRHEA, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 44 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HIV, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 45 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SYPHILIS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 46 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 47 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 48 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 49 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR POLYCYSTIC OVARY SYNDROME, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 50 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OVULATION DISORDERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 51 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 52 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR PREGNANCY TESTING, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 53 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 54 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 55 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 56 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 57 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 58 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 59 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HYPERMARKET/SUPERMARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 60 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 61 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 62 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR E-COMMERCE PLATFORMS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 63 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 64 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 65 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HOSPITALS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 66 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 67 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR HOME SETTINGS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 68 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 69 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 70 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 71 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 72 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 73 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 74 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 75 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 76 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 77 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 78 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 79 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 80 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 81 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 82 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 83 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 84 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 85 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 86 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 87 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 88 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 89 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 90 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 91 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 92 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 93 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 94 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 95 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 96 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 97 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 98 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 99 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 100 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 101 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 102 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 103 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 104 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 105 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 106 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 107 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 108 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 109 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 110 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 111 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 112 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 113 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 114 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 115 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 116 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 117 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 118 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 119 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 120 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 121 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 122 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 123 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 124 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 125 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 126 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 127 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 128 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 129 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 130 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 131 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 132 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 133 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 134 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 135 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 136 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 137 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 138 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 139 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 140 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 141 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 142 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 143 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 144 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 145 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 146 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 147 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 148 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 149 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 150 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 151 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 152 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 153 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 154 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 155 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 156 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 157 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 158 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 159 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 160 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 161 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 162 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 163 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 164 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 165 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 166 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 167 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 168 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 169 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 170 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 171 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 172 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 173 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 174 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 175 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 176 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 177 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 178 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 179 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 180 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 181 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 182 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 183 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 184 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 185 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 186 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 187 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 188 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 189 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 190 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 191 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 192 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 193 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 194 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 195 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 196 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 197 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 198 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 199 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 200 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 201 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 202 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 203 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 204 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 205 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 206 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 207 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 208 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 209 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 210 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 211 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 212 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 213 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 214 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 215 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 216 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 217 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 218 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 219 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 220 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 221 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 222 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 223 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 224 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 225 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 226 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 227 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 228 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 229 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 230 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 231 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 232 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 233 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 234 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 235 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 236 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 237 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 238 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 239 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 240 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 241 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 242 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 243 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 244 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 245 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 246 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 247 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 248 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 249 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 250 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 251 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 252 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 253 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 254 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 255 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 256 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 257 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 258 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 259 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 260 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 261 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 262 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 263 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 264 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 265 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 266 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 267 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 268 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 269 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 270 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 271 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 272 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 273 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 274 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 275 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 276 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 277 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
  • TABLE 278 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 279 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 280 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 281 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 282 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 283 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 284 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 285 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 286 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 287 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 288 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 289 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 290 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 291 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 292 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 293 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 294 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 295 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 296 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 297 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 298 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 299 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 300 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 301 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 302 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 303 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 304 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 305 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 306 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 307 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 308 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 309 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 310 SINGAPORE ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 311 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 312 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 313 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 314 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 315 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 316 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 317 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 318 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 319 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 320 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 321 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 322 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 323 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 324 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 325 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 326 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 327 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 328 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 329 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 330 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 331 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 332 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 333 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 334 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 335 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 336 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 337 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 338 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 339 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 340 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 341 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 342 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 343 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 344 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 345 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 346 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 347 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 348 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 349 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 350 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 351 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 352 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 353 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 354 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 355 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 356 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 357 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 358 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 359 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 360 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 361 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 362 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 363 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 364 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 365 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 366 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 367 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 368 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 369 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 370 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 371 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 372 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 373 REST OF SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 374 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 375 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (METRIC TON)
  • TABLE 376 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 377 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2032 (USD MILLION)
  • TABLE 378 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2032 (USD MILLION)
  • TABLE 379 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 380 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 381 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 382 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 383 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 384 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 385 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 386 REST OF THE WORLD POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 387 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 388 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 389 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 390 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 391 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 392 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 393 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 394 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 395 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 396 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 397 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 398 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 399 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 400 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 401 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 402 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 403 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 404 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 405 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 406 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 407 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 408 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 409 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 410 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 411 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION, 2019-2032 (USD MILLION)
  • TABLE 412 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 413 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 414 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 415 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 416 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 417 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 418 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 419 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 420 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 421 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 422 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 423 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 424 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 425 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 426 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 427 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 428 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 429 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 430 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 431 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 432 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 433 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 434 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 435 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 436 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 437 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 438 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 439 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 440 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 441 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 442 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 443 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 444 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 445 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 446 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 447 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 448 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 449 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 450 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 451 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 452 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 453 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 454 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 455 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 456 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 457 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 458 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 459 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 460 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2032 (USD MILLION)
  • TABLE 461 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2032 (USD MILLION)
  • TABLE 462 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2032 (USD MILLION)
  • TABLE 463 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2032 (USD MILLION)
  • TABLE 464 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY 2019-2032 (USD MILLION)
  • TABLE 465 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2032 (USD MILLION)
  • TABLE 466 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED DISEASE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 467 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 468 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
  • TABLE 469 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 470 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE, 2019-2032 (USD MILLION)
  • TABLE 471 REST OF SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2032 (USD MILLION)
  • TABLE 472 PRODUCT LAUNCH
  • TABLE 473 TECHNOLOGY LAUNCH
  • TABLE 474 AQUISITION
  • TABLE 475 PRODUCT RECOGNISTION
  • TABLE 476 SWISS PRECISION DIAGNOSTICS GMBH: PRODUCTS OFFERED
  • TABLE 477 SWISS PRECISION DIAGNOSTICS GMBH: PRICE ANALYSIS
  • TABLE 478 SWISS PRECISION DIAGNOSTICS GMBH: TECHNOLOGY ANALYSIS
  • TABLE 479 SWISS PRECISION DIAGNOSTICS GMBH: KEY DEVELOPMENTS
  • TABLE 480 WONDFO: PRODUCTS OFFERED
  • TABLE 481 WONDFO: TECHNOLOGY
  • TABLE 482 WONDFO: KEY DEVELOPMENTS
  • TABLE 483 CHURCH & DWIGHT CO., INC.: PRODUCTS OFFERED
  • TABLE 484 CHURCH & DWIGHT CO., INC.: PRICE ANALYSIS
  • TABLE 485 CHURCH & DWIGHT CO., INC.: TECHNOLOGY ANALYSIS
  • TABLE 486 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.: PRODUCTS OFFERED
  • TABLE 487 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.: TECHNOLOGY ANALYSIS
  • TABLE 488 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.: KEY DEVELOPMENTS
  • TABLE 489 W.H.P.M., INC.: PRODUCTS OFFERED
  • TABLE 490 W.H.P.M., INC.: TECHNOLOGY ANALYSIS
  • TABLE 491 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 492 SEKISUI DIAGNOSTICS: TECHNOLOGY ANALYSIS
  • TABLE 493 INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 494 INNOVITA BIOLOGICAL TECHNOLOGY CO., LTD.: TECHNLOGY ANALYSIS
  • TABLE 495 YANGZHOU VIOMED CO., LTD.: PRODUCTS OFFERED
  • TABLE 496 YANGZHOU VIOMED CO., LTD.: TECHNLOGY ANALYSIS
  • TABLE 497 COFOE MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 498 COFOE MEDICAL TECHNOLOGY CO., LTD.: TECHNLOGY ANALYSIS
  • TABLE 499 CHUNGDO PHARM CO., LTD.: PRODUCT OFFERED
  • TABLE 500 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 501 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.: TECHNOLOGY ANALYSIS
  • TABLE 502 EASY HEALTHCARE CORPORATION: PRODUCTS OFFERED
  • TABLE 503 EASY HEALTHCARE CORPORATION: TECHNOLOGY

LIST OF FIGURES

  • FIGURE 1 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET: STRUCTURE
  • FIGURE 2 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2024-2032)
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET
  • FIGURE 6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2023 & 2032 (USD MILLION)
  • FIGURE 7 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY PRODUCT, 2023
  • FIGURE 8 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2023 & 2032 (USD MILLION)
  • FIGURE 9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY AGE, 2023
  • FIGURE 10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2023 & 2032 (USD MILLION)
  • FIGURE 11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY SAMPLE TYPE, 2023
  • FIGURE 12 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2023 & 2032 (USD MILLION)
  • FIGURE 13 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY TEST TYPE, 2023
  • FIGURE 14 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2023 & 2032 (USD MILLION)
  • FIGURE 15 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY TECHNOLOGY, 2023
  • FIGURE 16 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION)
  • FIGURE 17 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY APPLICATION, 2023
  • FIGURE 18 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION)
  • FIGURE 19 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023
  • FIGURE 20 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2023 & 2032 (USD MILLION)
  • FIGURE 21 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY END USER, 2023
  • FIGURE 22 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY REGION, 2023 & 2032 (USD MILLION)
  • FIGURE 23 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY REGION, 2023
  • FIGURE 24 NORTH AMERICA MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION)
  • FIGURE 25 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 26 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY COUNTRY, 2023
  • FIGURE 27 EUROPE MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION)
  • FIGURE 28 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 29 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY COUNTRY, 2023
  • FIGURE 30 ASIA-PACIFIC MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION)
  • FIGURE 31 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 32 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 33 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 34 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 35 REST OF THE WORLD MARKET ANALYSIS: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, 2019-2032 (USD MILLION)
  • FIGURE 36 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 37 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 38 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
  • FIGURE 39 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY, 2023 (%)
  • FIGURE 40 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
  • FIGURE 41 COMPETITOR DASHBOARD: GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET
  • FIGURE 42 SWISS PRECISION DIAGNOSTICS GMBH: SWOT ANALYSIS
  • FIGURE 43 WONDFO: SWOT ANALYSIS
  • FIGURE 44 CHURCH & DWIGHT CO., INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 45 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS
  • FIGURE 46 SEKISUI DIAGNOSTICS: SWOT ANALYSIS
  • FIGURE 47 COFOE MEDICAL TECHNOLOGY CO., LTD.: SWOT ANALYSIS
  • FIGURE 48 ECONAS BIOPHARMACEUTICAL TECHNOLOGY CO., LTD.: SWOT ANALYSIS